Newer antihyperglycaemic medications, such as glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, which have demonstrated beneficial effects in reducing the risk of cardiovascular events, including stroke, MI and vascular mortality, may be considered viable options. The gene discussed is SLC5A2; the disease is stroke disorder.